C4 Therapeutics (CCCC) EBIT (QoQ) (2019 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) EBIT (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 492.07 Mn | 238.41 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.90% |
| Mar 31, 2026 | -20.05% |
| Dec 31, 2025 | 32.74% |
| Sep 30, 2025 | -20.74% |
| Jun 30, 2025 | 2.27% |
| Mar 31, 2025 | 22.66% |
| Dec 31, 2024 | -33.51% |
| Sep 30, 2024 | -31.72% |
| Jun 30, 2024 | 33.45% |
| Mar 31, 2024 | 13.92% |
| Dec 31, 2023 | -34.59% |
| Sep 30, 2023 | 25.98% |
| Jun 30, 2023 | -3.70% |
| Mar 31, 2023 | 5.39% |
| Dec 31, 2022 | -17.87% |
| Sep 30, 2022 | -18.64% |
| Jun 30, 2022 | 12.70% |
| Mar 31, 2022 | -105.63% |
| Dec 31, 2021 | 37.10% |
| Sep 30, 2021 | -9.67% |